Immunomodulatory Effects of Tigecycline in Balb/C Mice

1. International Conference of Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline, Immunotoxicity Studies for Human Pharmaceuticals S8, Current Step 4 version; Geneva, September 2005, https://www.ich.org/filadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S8/Step4/S8/Guideline.pdf; last access date April 05, 2018.Search in Google Scholar

2. United State Office of Technology Assesment, Identifying and Controlling Immunotoxic Substances: Background Paper, OTA-BP-BA-75, US Government Printing Office, Washington (DC), April 1991.Search in Google Scholar

3. C.-S. Lee and Y. Doi, Therapy of infections due to carbapenem-resistant gram-negative pathogens, Infect. Chemother. 46 (2014) 149-164; https://doi.org/10.3947/ic.2014.46.3.14910.3947/ic.2014.46.3.149Search in Google Scholar

4. T. M. Wyeth, Product Monograph Tygacil®Tigecycline for Injection, Pfizer Canada Inc, Kirkland (Quebec), Canada, 2014, pp. 10-12.10.1016/S1365-6937(14)70398-3Search in Google Scholar

5. G. Bucaneve, A. Micozzi, M. Picardi, S. Ballanti, N. Cascavilla, P. Salutari, G. Specchia, R. Fanci, M. Luppi, L. Cudillo, R. Cantaffa, G. Milone, M. Bocchia, G. Martinelli, M. Offidani, A. Chierichini, F. Fabbiano, G. Quarta, V. Primon, B. Martino, A. Manna, E. Zuffa, A. Ferrari, G. Gentile, R. Foa and A. Del Favero, Results of a multicenter, controlled, randomized clinical trial evaluating the combination of piperacillin/tazobactam and tigecycline in high-risk hematologic patients with cancer with febrile neutropenia, J. Clin. Oncol. 32 (2014) 1463-1471; https://doi.org/10.1200/jco.2013.51.696310.1200/JCO.2013.51.696324733807Search in Google Scholar

6. N. Maximova, D. Zanon, F. Verzegnassi and M. Granzotto, Neutrophils engraftment delay during tigecycline treatment in 2 bone marrow-transplanted patients, J. Pediatr. Hematol. Oncol. 35 (2013) e33-e37; https://doi.org/10.1097/MPH.0b013e318279eec210.1097/MPH.0b013e318279eec223171996Search in Google Scholar

7. Q. Zhang, S. Zhou and J. Zhou, Tigecycline treatment causes a decrease in fibrinogen levels, Antimicrob. Agents Chemother. 59 (2015) 1650-1655; https://doi.org/10.1128/aac.04305-1410.1128/AAC.04305-14432577225547356Search in Google Scholar

8. Food and Drug Administeration, FDA Safety Communication: Increased Risk of Death with Tygacil (Tigecycline) Compared to Other Antibiotics Used to Treat Similar Infections, Silver Spring (MD), USA 2010; https://fda.gov/Drug/DrugSafety/ucm223470.htm; last access date June 20, 2018Search in Google Scholar

9. R. Cockeran, N. D. Mutepe, A. J. Theron, G. R. Tintinger, H. C. Steel, P. I. Stivaktas, G. A. Richards, C. Feldman and R. Anderson, Calcium-dependent potentiation of the pro-inflammatory functions of human neutrophils by tigecycline in vitro, J. Antimicrob. Chemother. 67 (2012) 130-137; https://doi.org/10.1093/jac/dkr44110.1093/jac/dkr44122010205Search in Google Scholar

10. A. Naess, H. Andreeva and S. Sornes, Tigecycline attenuates polymorphonuclear leukocyte (PMN) receptors but not functions, Acta Pharm. 61 (2011) 297-302; https://doi.org/10.2478/v10007-011-0024-410.2478/v10007-011-0024-421945908Search in Google Scholar

11. C. M. Salvatore, C. Techasaensiri, C. Tagliabue, K. Katz, N. Leos, A. M. Gomez, G. H. McCracken and R. D. Hardy, Tigecycline t herapy significantly reduces t he concentrations of i nflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia, Antimicrob. Agents Chemother. 53 (2009) 1546-1551; https://doi.org/10.1128/aac.00979-0810.1128/AAC.00979-08266308419139287Search in Google Scholar

12. S. Pichereau, J. J. Moran, M. S. Hayney, S. K. Shukla, G. Sakoulas and W. E. Rose, Concentrationdependent effects of antimicrobials on Staphylococcus aureus toxin-mediated cytokine production from peripheral blood mononuclear cells, J. Antimicrob. Chemother. 67 (2012) 123-129; https://doi.org/10.1093/jac/dkr41710.1093/jac/dkr41721980070Search in Google Scholar

13. R. Saliba, L. Paasch and A. El Solh, Tigecycline attenuates staphylococcal superantigen-induced T-cell proliferation and production of cytokines and chemokines, Immunopharmacol. Immunotoxicol. 31 (2009) 583-588; https://doi.org/10.3109/0892397090283867210.3109/0892397090283867219874226Search in Google Scholar

14. F. Traunmuller, C. Thallinger, J. Hausdorfer, C. Lambers, S. Tzaneva, T. Kampitsch, G. Endler and C. Joukhadar, Tigecycline has no effect on cytokine release in an ex vivo endotoxin model of human whole blood, Int. J. Antimicrob. Agents. 33 (2009) 583-586; https://doi.org/10.1016/j.ijantimicag.2008.11.00810.1016/j.ijantimicag.2008.11.008Search in Google Scholar

15. M. K. Mohammad, I. M. Al-Masri, M. O. Taha, M. A. Al-Ghussein, H. S. Alkhatib, S. Najjar and Y. Bustanji, Olanzapine inhibits glycogen synthase kinase-3beta: an investigation by docking simulation and experimental validation, Eur. J. Pharmacol. 584 (2008) 185-191; https://doi.org/10.1016/j.ejphar.2008.01.01910.1016/j.ejphar.2008.01.019Search in Google Scholar

16. Committee for the Update of the Guide for the Care and Use of Laboratory Animals, National Research Council of the National Academies, Guide for the Care and Use of Laboratory Animals, 8th ed.; Washington DC, 2011, https://grants.nih.gov/grants/olaw/guide-for-the-care-and-use-of-laboratory-animals.pdf; last access date June 22, 2018.Search in Google Scholar

17. N. Kasbekar, Tigecycline: a new glycylcycline antimicrobial agent, Am. J. Health Syst. Pharm. 63 (2006) 1235-1243; https://doi.org/10.2146/ajhp05048710.2146/ajhp050487Search in Google Scholar

18. Y. Abdelrahman, M. Fararjeh, W. Abdel-Razeq, M. K. Mohammad and Y. Bustanji, Assessment of possible immunotoxicity of the antipsychotic drug clozapine, J. Pharm. Parmacol. 66 (2014) 378-386;https://doi.org/10.1111/jphp.1215010.1111/jphp.12150Search in Google Scholar

19. M. Fararjeh, M. K. Mohammad, Y. Bustanji, H. Alkhatib and S. Abdalla, Evaluation of immunosuppression induced by metronidazole in Balb/c mice and human peripheral blood lymphocytes, Int. Immunopharmacol. 8 (2008) 341-350; https://doi.org/10.1016/j.intimp.2007.10.01810.1016/j.intimp.2007.10.018Search in Google Scholar

20. D. D. Dietz, K. M. Abdo, J. K. Haseman, S. L. Eustis and J. E. Huff, Comparative toxicity and carcinogenicity studies of tetracycline and oxytetracycline in rats and mice, Fundam. Appl. Toxicol. 17 (1991) 335-346.10.1016/0272-0590(91)90223-QSearch in Google Scholar

21. J. M. Korth-Bradley, S. M. Troy, K. Matschke, G. Muralidharan, R. J. Fruncillo, J. L. Speth and D. G. Raible, Tigecycline pharmacokinetics in subjects with various degrees of renal function, J. Clin. Pharmacol. 52 (2012) 1379-1387; https://doi.org/10.1177/009127001141693810.1177/009127001141693821953572Search in Google Scholar

22. J. Rello, Pharmacokinetics, pharmacodynamics, safety and tolerability of tigecycline, J. Chemother. 17 (Suppl. 1) (2005) 12-22; https://doi.org/10.1179/joc.2005.17.Supplement-1.12.10.1179/joc.2005.17.Supplement-1.1216285354Search in Google Scholar

23. M. Shinkai, M. O. Henke and B. K. Rubin, Macrolide antibiotics as immunomodulatory medications: proposed mechanisms of action, Pharmacol. Ther. 117 (2008) 393-405; https://doi.org/10.1016/j.pharmthera.2007.11.00110.1016/j.pharmthera.2007.11.00118289694Search in Google Scholar

24. S. Farhath, P. Vijaya and M. Vimal, Immunomodulatory activity of geranial, geranial acetate, gingerol, and eugenol essential oils: evidence for humoral and cell-mediated responses, Avicenna J. Phytomed. 3 (2013) 224-230Search in Google Scholar

25. G. A. Pankey, Tigecycline, J. Antimicrob. Chemother. 56 (2005) 470-480.10.1093/jac/dki24816040625Search in Google Scholar

26. M. Schwarz, R. Sunder-Plassmann, A. Cerwenka, W. F. Pickl and W. Holter, [Regulation of cytokine production by human T-lymphocytes in allergic immune response], Wien Klin. Wochenschr. 105 (1993) 672-676.Search in Google Scholar

27. N. Y. A. Hemdan, A. M. Abu El-Saad and U. Sack, The role of T helper (TH)17 cells as a doubleedged sword in the interplay of infection and autoimmunity with a focus on xenobiotic-induced immunomodulation, Clin. Dev. Immunol. 2013 (2013) Article ID 374769 (13 pages); https://doi.org/10.1155/2013/37476910.1155/2013/374769378765224151516Search in Google Scholar

28. P. Miossec and J. K. Kolls, Targeting IL-17 and TH17 cells in chronic inflammation, Nat. Rev. Drug Discov. 11 (2012) 763-776; https://doi.org/10.1038/nrd379410.1038/nrd379423023676Search in Google Scholar

29. R. Joks and H. G. Durkin, Non-antibiotic properties of tetracyclines as anti-allergy and asthma drugs, Pharmacol. Res. 64 (2011) 602-609; https://doi.org/10.1016/j.phrs.2011.04.00110.1016/j.phrs.2011.04.00121501686Search in Google Scholar

30. T. Polhill, G. Y. Zhang, M. Hu, A. Sawyer, J. J. Zhou, M. Saito, K. E. Webster, Y. Wang, Y. Wang, S. T. Grey, J. Sprent, D. C. Harris, S. I. Alexander and Y. M. Wang, IL-2/IL-2Ab complexes induce regulatory T cell expansion and protect against proteinuric CKD, J. Am. Soc. Nephrol. 23 (2012) 1303-1308; https://doi.org/10.1681/asn.201111113010.1681/ASN.2011111130340228622677553Search in Google Scholar

31. M. Mizui, T. Koga, L. A. Lieberman, J. Beltran, N. Yoshida, M. C. Johnson, R. Tisch and G. C. Tsokos, IL-2 protects lupus-prone mice from multiple end-organ damage by limiting CD4-CD8- IL- 17-producing T cells, J. Immunol. 193 (2014) 2168-2177; https://doi.org/10.4049/jimmunol.140097710.4049/jimmunol.1400977413501625063876Search in Google Scholar